Clin Gastroenterology H: Normalization of fecal calcitonin within 12 months of diagnosis is associated with a reduced risk of disease progression in patients with Crohn's disease.

Because Crohn's disease has the characteristics of recurrent seizures, most patients need to take long-term medications to maintain the relief of the disease and prevent recurrence.
condition determines the treatment plan, so patients need to regularly assess the condition.
endoscopy is the gold standard for evaluating the activity of IBD disease, can very intuitively observe the performance of the intestinal mucous membranes and can be pathological biopsy.
but endoscopy is invasive, the patient needs an empty stomach before the examination, and the cost is relatively high, in the short term repeated monitoring is not easy to accept.
levels of poop calcification protein increased specifically in the feces of IBD patients and remained stable for a long time, and could be preserved at room temperature for 1 week.
It is well related to the colonoscopy, has the advantages of easy sampling, high sensitivity and specificity, can be repeated detection in a short period of time, easy to be accepted by asymptomatic people, especially in judging disease activity and recurrence has guiding significance.
, researchers have suggested that poop caloglobin can be used not only as a biological indicator of inflammatory changes, but also as a predictive indicator of disease prognosm.
long-term follow-up of fecal calcitonin levels within one year of diagnosis in patients with Crohn's disease found that the normalization of fecal calcitonin was associated with a good prognosis of the disease.
DOI: The researchers conducted a retrospective analysis of all CD patients diagnosed at a medical center between 2005 and 2017, including patients who were diagnosed with a measurement of fecal calcitonin (FC) of 250 ?g/g, and who also had at least one follow-up FC measurement within the first 12 months of diagnosis and 12 months of follow-up.
the main observed endpoint is the time of the first progression of the disease (Montreal's disease behavior from B1 to B2/3, B2 to B3 or new disease progression composite; CD-related surgery occurs; or CD-related hospitalization).
a total of 375 patients were included in the study, with a medium follow-up time of 5.3 years (3.1-7.4 years for the quarter spacing).
43.5 percent of patients normalized FC within 12 months of diagnosis.
risk of compound disease progression was significantly reduced in patients with normal FC (risk ratio of 0.36; 95% CI was 0.24-0.53; P.lt;.001).
they also had a lower risk of reaching any single end of progression (Montreal Behavior or New Disease Progress HR, 0.22; 95% CI, 0.11-0.45; P .lt;.001; Hospitalized HR, 0.33; 95%CI, 0.21 -0.53; P .lt;.001; Surgical HR, 0.39; 95%CI, 0.19-0.78; P - .008).
, fecal calcitonin testing can provide a reliable basis for the diagnosis, identification and follow-up of Crohn's disease, which is worth popularization and application.
.